Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

The Role of Heme Oxygenase 1 in the Protective Effect of Caloric Restriction against Diabetic Cardiomyopathy.

Waldman M, Nudelman V, Shainberg A, Zemel R, Kornwoski R, Aravot D, Peterson SJ, Arad M, Hochhauser E.

Int J Mol Sci. 2019 May 16;20(10). pii: E2427. doi: 10.3390/ijms20102427.

2.

25-Hydroxyvitamin D Inhibits Hepatitis C Virus Production in Hepatocellular Carcinoma Cell Line by a Vitamin D Receptor-Independent Mechanism.

Ravid A, Rapaport N, Issachar A, Erman A, Bachmetov L, Tur-Kaspa R, Zemel R.

Int J Mol Sci. 2019 May 13;20(9). pii: E2367. doi: 10.3390/ijms20092367.

3.

Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus.

Witt-Kehati D, Fridkin A, Alaluf MB, Zemel R, Shlomai A.

Transl Oncol. 2018 Apr;11(2):511-517. doi: 10.1016/j.tranon.2018.02.015. Epub 2018 Mar 7.

4.

Bone marrow and nonbone marrow Toll like receptor 4 regulate acute hepatic injury induced by endotoxemia.

Hochhauser E, Avlas O, Fallach R, Bachmetov L, Zemel R, Pappo O, Shainberg A, Ben Ari Z.

PLoS One. 2013 Aug 15;8(8):e73041. doi: 10.1371/journal.pone.0073041. eCollection 2013.

5.

The use of epitope arrays in immunodiagnosis of infectious disease: hepatitis C virus, a case study.

Siman-Tov DD, Zemel R, Tur Kaspa R, Gershoni JM.

Anal Biochem. 2013 Jan 15;432(2):63-70. doi: 10.1016/j.ab.2012.09.025. Epub 2012 Sep 24.

PMID:
23017878
6.

Reduced hepatic injury in Toll-like receptor 4-deficient mice following D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure.

Ben Ari Z, Avlas O, Pappo O, Zilbermints V, Cheporko Y, Bachmetov L, Zemel R, Shainberg A, Sharon E, Grief F, Hochhauser E.

Cell Physiol Biochem. 2012;29(1-2):41-50. doi: 10.1159/000337585. Epub 2012 Mar 1.

7.

Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin.

Shapira A, Shapira S, Gal-Tanamy M, Zemel R, Tur-Kaspa R, Benhar I.

PLoS One. 2012;7(2):e32320. doi: 10.1371/journal.pone.0032320. Epub 2012 Feb 16.

8.

Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes.

Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, Zemel R.

Hepatology. 2011 Nov;54(5):1570-9. doi: 10.1002/hep.24575.

PMID:
21793032
9.

The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma.

Zemel R, Issachar A, Tur-Kaspa R.

Clin Liver Dis. 2011 May;15(2):261-79, vii-x. doi: 10.1016/j.cld.2011.03.001. Review.

PMID:
21689612
10.

Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain.

Shapira A, Gal-Tanamy M, Nahary L, Litvak-Greenfeld D, Zemel R, Tur-Kaspa R, Benhar I.

PLoS One. 2011 Jan 14;6(1):e15916. doi: 10.1371/journal.pone.0015916.

11.

Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.

Gal-Tanamy M, Zemel R, Bachmatov L, Jangra RK, Shapira A, Villanueva RA, Yi M, Lemon SM, Benhar I, Tur-Kaspa R.

Antiviral Res. 2010 Oct;88(1):95-106. doi: 10.1016/j.antiviral.2010.08.001. Epub 2010 Aug 10.

12.

Expression of liver-specific markers in naïve adipose-derived mesenchymal stem cells.

Zemel R, Bachmetov L, Ad-El D, Abraham A, Tur-Kaspa R.

Liver Int. 2009 Oct;29(9):1326-37. doi: 10.1111/j.1478-3231.2009.02054.x. Epub 2009 Jun 5.

PMID:
19515222
13.

Inhibition of hepatitis C virus RNA replicons by peptide aptamers.

Trahtenherts A, Gal-Tanamy M, Zemel R, Bachmatov L, Loewenstein S, Tur-Kaspa R, Benhar I.

Antiviral Res. 2008 Mar;77(3):195-205. doi: 10.1016/j.antiviral.2007.12.013. Epub 2008 Jan 22.

PMID:
18243349
14.

Iatrogenic transmission of hepatitis C virus (HCV) by an anesthesiologist: comparative molecular analysis of the HCV-E1 and HCV-E2 hypervariable regions.

Shemer-Avni Y, Cohen M, Keren-Naus A, Sikuler E, Hanuka N, Yaari A, Hayam E, Bachmatov L, Zemel R, Tur-Kaspa R.

Clin Infect Dis. 2007 Aug 15;45(4):e32-8. Epub 2007 Jul 10.

PMID:
17638183
15.

Development of specific antibodies to an ARF protein in treated patients with chronic HCV infection.

Cohen M, Bachmatov L, Ben-Ari Z, Rotman Y, Tur-Kaspa R, Zemel R.

Dig Dis Sci. 2007 Sep;52(9):2427-32. Epub 2007 Apr 10.

PMID:
17436105
16.

HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.

Gal-Tanamy M, Zemel R, Berdichevsky Y, Bachmatov L, Tur-Kaspa R, Benhar I.

J Mol Biol. 2005 Apr 15;347(5):991-1003.

PMID:
15784258
17.

Inhibition of hepatitis C virus NS3-mediated cell transformation by recombinant intracellular antibodies.

Zemel R, Berdichevsky Y, Bachmatov L, Benhar I, Tur-Kaspa R.

J Hepatol. 2004 Jun;40(6):1000-7.

PMID:
15158342
18.

A novel high throughput screening assay for HCV NS3 serine protease inhibitors.

Berdichevsky Y, Zemel R, Bachmatov L, Abramovich A, Koren R, Sathiyamoorthy P, Golan-Goldhirsh A, Tur-Kaspa R, Benhar I.

J Virol Methods. 2003 Feb;107(2):245-55.

PMID:
12505640
19.

p73 overexpression and nuclear accumulation in hepatitis C virus-associated hepatocellular carcinoma.

Zemel R, Koren C, Bachmatove L, Avigad S, Kaganovsky E, Okon E, Ben-Ari Z, Grief F, Ben-Yehoyada M, Shaul Y, Tur-Kaspa R.

Dig Dis Sci. 2002 Apr;47(4):716-22.

PMID:
11991598

Supplemental Content

Loading ...
Support Center